Lipoprotein(a), usually written as Lp(a) and pronounced “L-P-little-a,” is a cholesterol-carrying particle whose blood levels are overwhelmingly set by the genes you inherited. Unlike LDL cholesterol or triglycerides, Lp(a) barely budges with diet, exercise, or most standard medications. Roughly one in five people worldwide walks around with levels high enough to meaningfully raise their risk of heart attack, stroke, and aortic valve disease, often without knowing it. What makes Lp(a) unusual among cardiovascular risk factors is that gap between how important it is and how rarely it gets checked.
Why Your Lp(a) Level Is Mostly Out of Your Hands
The single biggest driver of your Lp(a) concentration is a gene called LPA, which encodes the protein that gives the particle its distinctive structure. The LPA gene is remarkably variable from person to person: it contains a stretch of repeating segments called kringle IV type 2 domains, and the number of copies you carry can range from just a few to more than 40.1PubMed Central. Genetics and Pathophysiological Mechanisms of Lipoprotein(a)-Associated Cardiovascular Risk Fewer repeats generally mean a smaller, more efficiently produced protein and higher Lp(a) levels in the blood. More repeats tend to yield a larger protein that the liver assembles more slowly, resulting in lower circulating levels. Beyond these repeat-number differences, individual single-letter DNA changes (single-nucleotide variants) in and around LPA also nudge concentrations up or down.2PubMed Central. Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases
Because you inherit one copy of LPA from each parent, elevated Lp(a) is transmitted as a codominant trait, meaning both copies contribute to the level you end up with.1PubMed Central. Genetics and Pathophysiological Mechanisms of Lipoprotein(a)-Associated Cardiovascular Risk In practical terms, if one of your parents has very high Lp(a), there is a substantial chance you do too. That is why guidelines increasingly recommend testing first-degree relatives of anyone found to have elevated levels.
Non-Genetic Factors That Can Push Levels Higher
Although genetics accounts for the lion’s share of variation, a handful of medical conditions can raise Lp(a) independently. Kidney disease is the best-documented non-genetic influence. In people with protein-losing kidney conditions such as nephrotic syndrome, the liver ramps up production of Lp(a). In patients on dialysis who happen to carry genetically large protein forms, reduced clearance keeps levels elevated. Tellingly, kidney transplantation tends to bring Lp(a) back down, confirming that the spike is acquired rather than inherited.3PubMed Central. The role of lipoprotein (a) in chronic kidney disease
Hypothyroidism, systemic inflammatory conditions, pregnancy, and growth hormone therapy have all been linked to increases in Lp(a) as well.4American College of Cardiology. An Update on Lipoprotein(a): The Latest on Testing, Treatment, and Guideline Recommendations The practical takeaway is that a single Lp(a) measurement taken during one of these states could overestimate your true baseline. But for most healthy people, the number stays remarkably stable over a lifetime, which is why a single test is often considered sufficient.
How Lp(a) Damages Blood Vessels
Lp(a) is not just another cholesterol carrier. It has a unique structural design that makes it harmful through at least two overlapping pathways: it promotes plaque buildup in arteries, and it interferes with the body’s ability to dissolve blood clots.
The particle carries a payload of oxidized phospholipids on its surface, and these molecules trigger inflammation in artery walls. Research using human blood samples shows that Lp(a) activates a pro-inflammatory response in white blood cells called monocytes, and this effect was substantially reduced when the oxidized phospholipids were removed or chemically inactivated.5PubMed Central. Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans In other words, it is not just the cholesterol content of Lp(a) that matters. The inflammatory cargo it carries is a big part of the problem.
The second mechanism involves clot dissolution. The protein on Lp(a) looks structurally similar to plasminogen, a molecule the body uses to break down blood clots. Because of that resemblance, Lp(a) competes with plasminogen for binding sites on clots and on the surfaces of blood-vessel cells, essentially shouldering aside the body’s clot-clearing machinery.6PubMed. Lipoprotein(a) inhibits plasminogen activation in a template-dependent manner The result is that clots stick around longer than they should. When the Lp(a) particle itself becomes oxidized, this anti-fibrinolytic effect gets even worse, because the oxidized form competes even more aggressively for fibrin binding.7PubMed Central. Investigation of the Influence of Lipoprotein(a) and Oxidized Lipoprotein(a) on Plasminogen Activation and Fibrinolysis So high Lp(a) creates a double hit: more inflammation driving plaque formation, and impaired clot breakdown making acute events like heart attacks more likely once a plaque ruptures.8Archives of Medical Science. Lipoprotein(a) and thromboembolism: current state of knowledge and unsolved issues – Section: Impaired fibrinolysis and increased PAI-1 expression
Cardiovascular Risks Tied to High Lp(a)
The strongest evidence links elevated Lp(a) to coronary artery disease and heart attack. A large multi-ethnic pooled analysis found that people with Lp(a) above the 90th percentile had roughly a 46% higher rate of major cardiovascular events compared with those below the 50th percentile, after adjusting for other risk factors. Lp(a) independently predicted heart attack, the need for artery-opening procedures, stroke, and death from coronary disease, though it did not predict overall mortality.9PubMed. Lipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic Pooled Prospective Cohort The risk rose in a graded fashion: even moderately elevated levels (75th to 90th percentile) carried about an 18% higher hazard than lower levels.
Peripheral artery disease, the narrowing of arteries in the legs, is another area where the evidence has strengthened. A 2025 review concluded that elevated Lp(a) is as potent a risk factor for peripheral artery disease as it is for coronary disease, linked not just to initial diagnosis but also to disease progression, the need for leg revascularization procedures, and even limb amputation.10PubMed. Lp(a) as a Risk Factor for Peripheral Artery Disease: Context Is Everything Earlier reviews had described the evidence for peripheral disease and carotid narrowing as less conclusive than for coronary disease,11PubMed Central. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives but newer data have been filling in that gap.
The Aortic Valve Connection
One of the more striking findings about Lp(a) is its link to calcific aortic valve stenosis, the progressive stiffening and narrowing of the aortic valve. Lp(a) is the main lipoprotein carrier of oxidized phospholipids in the blood, and those phospholipids promote both inflammation and calcification of valve tissue.12PubMed Central. Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis Studies of patients with existing valve disease have shown that higher Lp(a) and oxidized phospholipid levels are associated with faster progression and a greater need for valve replacement.13PubMed. Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis The association was especially pronounced in younger patients, where each incremental rise in Lp(a) had a bigger effect on how quickly the valve worsened.14PubMed Central. Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels: Secondary Analysis of a Randomized Clinical Trial
This connection matters because aortic stenosis has no proven drug treatment; once it progresses far enough, the only option is surgical or catheter-based valve replacement. If lowering Lp(a) could slow that progression, it would be a genuine breakthrough, and it is one of the reasons the new Lp(a)-lowering drugs in development are generating so much excitement.
Who Is Most Likely to Have High Levels
Lp(a) levels vary dramatically across ethnic groups, a reality that complicates any attempt to set a single universal risk threshold. Black individuals tend to have the highest median Lp(a) concentrations, followed by South Asians, then White, Hispanic, and East Asian populations.15PubMed. Lipoprotein(a) and ethnicities In one large U.S. analysis, nearly 63% of non-Hispanic Black individuals tested above 50 mg/dL, compared with about 31% of Mexican-origin patients.16PubMed Central. Lipoprotein(a) Levels in Disaggregated Racial and Ethnic Subgroups Across Atherosclerotic Cardiovascular Disease Risk Levels After adjustment, Black individuals had about 2.5 times the odds of exceeding that threshold compared with the reference group.
These differences are rooted in genetics, specifically in how LPA gene variants and kringle repeat numbers are distributed across populations. Elevated Lp(a) does appear to raise cardiovascular risk across all groups, but whether the same numerical cutoff means the same thing for every population is an open question that researchers have not fully resolved.15PubMed. Lipoprotein(a) and ethnicities For now, most guidelines use a single threshold, acknowledging that population-specific cutoffs might eventually be more appropriate.
Testing and the Measurement Problem
If you have had a standard lipid panel drawn, Lp(a) was almost certainly not included. It requires a separate order. A growing consensus among expert groups is that every adult should have Lp(a) measured at least once in their lifetime for risk stratification.17PubMed Central. Consensus and guidelines on lipoprotein(a) – seeing the forest through the trees The 2024 update from the U.S. National Lipid Association goes further, explicitly recommending universal measurement and flagging cascade screening of first-degree relatives when someone tests high.18PubMed. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice Not every country agrees: Australia’s Atherosclerosis Society, for example, still recommends selective screening focused on people with premature cardiovascular disease or intermediate-to-high calculated risk, rather than universal testing.19PubMed. Australian Atherosclerosis Society Position Statement on Lipoprotein(a): Clinical and Implementation Recommendations
There is a practical wrinkle with the test itself. Lp(a) can be reported in two different units: mass-based (mg/dL) or molar concentration (nmol/L), and converting between them is not straightforward. Because the Lp(a) particle varies in size from person to person, a simple conversion factor introduces errors that depend on each individual’s protein variant size.20PubMed. Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size The field is moving toward molar concentration (nmol/L) as the preferred standard, but many labs still report in mg/dL, which can make it hard to compare results from different providers or match them against guideline thresholds.
Under the NLA framework, levels below 75 nmol/L (roughly 30 mg/dL) are considered low risk, levels of 125 nmol/L (about 50 mg/dL) or above are high risk, and values between those two points fall into an intermediate category.18PubMed. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice If your lab reports in mg/dL and the reference range looks unfamiliar, ask your doctor which units were used and how they map to current guidelines.
Why Standard Treatments Do Not Work on Lp(a)
This is the part that frustrates both patients and clinicians. Statins, the most widely prescribed cholesterol drugs in the world, have little to no benefit on Lp(a) levels, and there is evidence suggesting they may actually raise them slightly.21PubMed Central. Statins and Lp(a): The plot thickens. Diet and exercise, which can meaningfully improve LDL cholesterol and triglycerides, have essentially no effect on Lp(a). This makes sense biologically: if the level is set primarily by how fast your liver produces the particle (which your genes dictate), then lifestyle changes that alter cholesterol metabolism through other pathways simply do not reach the relevant machinery.
For people with very high Lp(a) and progressive cardiovascular disease, lipoprotein apheresis is an option in some countries. This is a procedure similar to dialysis in which blood is run through a filter that physically removes Lp(a) particles. A single session can reduce Lp(a) by about 68%, and a five-year follow-up study found that regular apheresis dramatically cut the rate of cardiovascular events in treated patients.22PubMed Central / AHA Journals. Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization The catch is that apheresis needs to be repeated every one to two weeks, it is expensive, not widely available, and time-consuming. It remains a niche treatment reserved for the highest-risk patients.
Because there is currently no approved drug specifically targeting Lp(a), clinicians managing someone with high levels focus on aggressively controlling every other modifiable risk factor, especially LDL cholesterol, blood pressure, blood sugar, and smoking. The NLA explicitly recommends early, intensive risk factor management for these patients, including lipid-lowering drugs aimed at getting LDL as low as possible.18PubMed. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice
RNA-Based Drugs in Development
The treatment landscape may be about to change fundamentally. Several drugs that silence the LPA gene at the RNA level are in advanced clinical trials. These work by intercepting the genetic instructions for making the Lp(a) protein before it ever gets assembled, essentially turning down production at the source.23PubMed Central. Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease?
The most dramatic results so far come from olpasiran, a small interfering RNA drug given by injection. In a phase 2 trial, olpasiran reduced Lp(a) by over 95% at higher doses, with the largest dose achieving a virtually complete reduction that persisted whether patients received injections every 12 or every 24 weeks.24PubMed. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease Other drugs in the same general class, including pelacarsen (an antisense oligonucleotide), zerlasiran, and lepodisiran, have shown comparable ability to lower Lp(a) in early-stage trials.25PubMed. Advances in RNA-Based Therapies Targeted at Lipoprotein(a): Olpasiran in the Management of Atherosclerotic Cardiovascular Disease
The critical question these trials still have to answer is whether slashing Lp(a) levels actually translates into fewer heart attacks, strokes, and valve replacements. Lowering a biomarker is not the same as preventing disease. Large outcome trials designed to answer exactly that question are underway, and their results over the next few years will determine whether these drugs become mainstream treatments or remain promising curiosities. If the outcomes are positive, the implications extend beyond coronary disease: the possibility of slowing aortic valve calcification with a drug, rather than waiting for a surgical procedure, is one of the most anticipated potential benefits.
Lp(a) Levels in Children
Unlike many cardiovascular risk markers that creep up with age, Lp(a) reaches its stable adult level surprisingly early. A consensus document reported that blood levels generally settle by about age five, even though the LPA gene does not complete its full expression until around age twenty.26PubMed Central. Lipoprotein(a) in Children and Adolescents: Risk or Causal Factor for Cardiovascular Disease? A Narrative Review This means that a child tested at six or seven already provides a reasonable preview of the number they will carry for the rest of their life.
That early stability raises a question about when to screen. Current guidelines do not recommend universal Lp(a) testing in children, but for kids with a strong family history of very early heart disease or a parent with known high Lp(a), many lipid specialists will order the test. The rationale is simple: knowing early allows the family and their doctors to be more vigilant about other risk factors as the child grows up, even though there is no Lp(a)-specific drug approved for children.
How Hormones Alter Lp(a)
Estrogen is one of the few known influences that can reliably lower Lp(a). In a controlled crossover trial of postmenopausal women given oral conjugated estrogens, Lp(a) dropped in 14 out of 15 participants, with an average decrease of about 23%.27PubMed. Hormonal regulation of lipoprotein(a) levels: effects of estrogen replacement therapy on lipoprotein(a) and acute phase reactants in postmenopausal women A larger analysis from the HERS trial found that women on hormone therapy had median Lp(a) values about 17% to 23% lower than those on placebo, and the reduction held steady across three years of follow-up.28PubMed. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration
This does not mean hormone therapy is prescribed to lower Lp(a). The overall risk-benefit calculus of postmenopausal hormone therapy is complex and depends on a woman’s age, time since menopause, and personal health history. But the estrogen-Lp(a) connection does help explain why Lp(a) levels tend to rise after menopause and why premenopausal women sometimes test lower than would be predicted by their genetics alone. It is another reason a single Lp(a) measurement taken during a hormonally dynamic period, such as pregnancy or the menopause transition, might not reflect a person’s long-term baseline.
Barriers to Getting Tested
Despite the mounting evidence, Lp(a) testing remains surprisingly uncommon in routine clinical practice. A 2025 review described a persistent “implementation gap” between the evidence supporting measurement and what actually happens in doctor’s offices. Barriers include inconsistent insurance reimbursement, gaps in provider awareness, and the laboratory standardization issues already mentioned. The shift from selective screening (as recommended by the ACC/AHA in 2018) to the NLA’s 2024 universal-measurement recommendation reflects growing recognition that the old approach left too many high-risk people unidentified. But changing clinical habits takes time, and many primary care physicians still do not routinely order the test unless prompted by a cardiovascular event or a patient’s request.
If you are curious about your own Lp(a), asking your doctor to add it to your next blood draw is straightforward. The test is inexpensive, requires no fasting, and in most cases only needs to be done once. Given that elevated Lp(a) is common, completely silent, and changes how aggressively other risk factors should be managed, a single measurement carries an unusually high informational return for a simple blood test.